Page 865 - Read Online

Page 16 of 16 Silk et al. Hepatoma Res 2020;6:73 I http://dx.doi.org/10.20517/2394-5079.2020.61

2017;5:135-48.
40. Sohn KH, Oh SY, Lim KW, Kim MY, Lee SY, et al. Sorafenib induces delayed-onset cutaneous hypersensitivity: a case series. Allergy
Asthma Immunol Res 2015;7:304-7.
41. Mantovani A, Álvares-Da-Silva MR. Anaphylaxis preceded by erythema multiforme with sorafenib: first case report. Ann Hepatol
2019;18:777-9.
42. Trayes KP, Love G, Studdiford JS. Erythema multiforme: recognition and management. Am Fam Physician 2019;100:82-88.
43. Ayangco L, Rogers RS. Oral manifestations of erythema multiforme. Dermatol Clin 2003;21:195-205.
44. Sokumbi O, Wetter DA. Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. Int
J Dermatol 2012;51:889-902.
45. Choi MK, Woo HY, Heo J, Cho M, Kim GH, et al. Toxic epidermal necrolysis associated with sorafenib and tosufloxacin in a patient with
hepatocellular carcinoma. Ann Dermatol 2011;23:S404-7.
46. Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, Shear NH. Stevens-johnson syndrome and toxic epidermal necrolysis: an update. Am J
Clin Dermatol 2015;16:475-93.
47. Duong TA, Valeyrie-allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet 2017;390:1996-2011.
48. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol
2007;87:144-8.
49. Valeyrie-Allanore L, Wolkenstein P, Brochard L, Ortonne N, Maître B, et al. Open trial of ciclosporin treatment for Stevens-Johnson
syndrome and toxic epidermal necrolysis. Br J Dermatol 2010;163:847-53.
50. Paradisi A, Abeni D, Bergamo F, Ricci F, Didona D, et al. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol
2014;71:278-83.
51. Kannaiyan R, Mahadevan D. A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Rev Anticancer Ther
2018;18:1249-70.
52. Autier J, Mateus C, Wechsler J, Spatz A, Robert C. Cutaneous side effects of sorafenib and sunitinib. Ann Dermatol Venereol
2008;135:148-53; quiz 147, 154.
53. Eisai Inc. Lenvima (Lenvatinib) [package insert]. U.S. Food and Drug Administration website. Available from: https://www.accessdata.
fda.gov/drugsatfda_docs/label/2018/206947s007lbl.pdf. [Last accessed on 24 Sep 2020]
54. Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma
(METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17:917-27.
55. Exelixis. Cabometyx (Cabozantinib) [package insert]. U.S. Food and Drug Administration website. Available from: https://www.
accessdata.fda.gov/drugsatfda_docs/label/2019/208692s003lbl.pdf. [Last accessed on 24 Sep 2020]
56. Finn RS, Merle P, Granito A, Huang YH, Bodoky G, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for
HCC: additional analyses from the phase III RESORCE trial. J Hepatol 2018;69:353-8.
57. Grothey A, Sobrero AF, Siena S, Falcone A, Ychou M, et al. Time profile of adverse events (AEs) from regorafenib (REG) treatment
for metastatic colorectal cancer (mCRC) in the phase III CORRECT study. Available from: https://doi.org/10.1200/jco.2013.31.15_
suppl.3637. [Last accessed on 30 Sep 2020]
58. Sastre J, Argilés G, Benavides M, Feliú J, García-Alfonso P, et al. Clinical management of regorafenib in the treatment of patients with
advanced colorectal cancer. Clin Transl Oncol 2014;16:942-53.
59. Khan G, Moss RA, Braiteh F, Saltzman M. Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal
patient management. Cancer Manag Res 2014;6:93-103.
60. Grothey A, George S, van Cutsem E, Blay JY, Sobrero A, et al. Optimizing treatment outcomes with regorafenib: personalized dosing and
other strategies to support patient care. Oncologist 2014;19:669-80.
61. Mitchell J, Khoukaz T, McNeal D, Brent L. Adverse event management strategies: optimizing treatment with regorafenib in patients with
metastatic colorectal cancer. Clin J Oncol Nurs 2014;18:E19-25.
62. Bayer HealthCare Pharmaceuticals Inc. Stivarga (Regorafenib). U.S. Food and Drug Administration website. Available from: https://
www.accessdata.fda.gov/drugsatfda_docs/label/2013/204369lbl.pdf. [Last accessed on 24 Sep 2020]
63. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular
carcinoma patients treated with sorafenib. Oncologist 2010;15:85-92.
64. Shomura M, Kagawa T, Shiraishi K, Hirose S, Arase Y, et al. Skin toxicity predicts efficacy to sorafenib in patients with advanced
hepatocellular carcinoma. World J Hepatol 2014;6:670-6.
65. Sung MW, Finn RS, Qin S, Han K, Ikeda K, et al. Association between overall survival and adverse events with lenvatinib treatment in
patients with hepatocellular carcinoma (REFLECT). JCO 2019;37:317.
66. Abou-alfa GK, Meyer T, Cheng A, Cicin I, Bolondi L, et al. Association of adverse events (AEs) with efficacy outcomes for cabozantinib
(C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial. JCO 2019;37:4088.
67. Wakatsuki T, Shinozaki E, Suenaga M, Nakayama I, Matsushima T, et al. Associations between regorafenib-induced adverse events (AEs)
and efficacy in metastatic colorectal cancer (mCRC). JCO 2017;35:556.
68. Rimassa L, Danesi R, Pressiani T, Merle P. Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes
for patients with hepatocellular carcinoma. Cancer Treat Rev 2019;77:20-8.
69. Kong Y, Sun L, Hou Z, Zhang Y, Chen P, et al. Apatinib is effective for treatment of advanced hepatocellular carcinoma. Oncotarget
2017;8:105596-605.
70. Liu J, Li X, Zhang H, Chen G, Chen H, et al. Safety, pharmacokinetics and efficacy of donafenib in treating advanced hepatocellular
carcinoma: report from a phase 1b trial. Pharmazie 2019;74:688-93.